Compare Stocks

Auxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Toronto, Canada.

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.